European Network for Gynaecological Oncological Trial   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Berlin Germany (2007)

Organization Overview

First Clinical Trial
2013
NCT01847274
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ENGOT | European Network for Gynaecological Oncological Trial groups(ENGOT) | European Network of Gynaecological Oncological Trial Group (ENGOT) | European Network of Gynaecological Oncological Trial Groups (ENGOT) | European Network of Gynaecological Oncology Trial Groups (ENGOT) | The European Network for Gynaecological Oncological Trial groups (ENGOT)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Endometrial Neoplasms (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Hypersensitivity (Phase 3)

Ovarian Neoplasms (Phase 3)

Peritoneal Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 32